Loading cancer entity…
Loading cancer entity…
Clinical trials
28 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06429150 | Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma | not yet recruiting | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04166565 | Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease(EMN19) | active not recruiting | Phase 2 | 41 | Stichting European Myeloma NetworkNETWORK |
| 3 |
| Apr 20, 2026 |
| clinicaltrials |
| NCT04174196 | A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma | active not recruiting | Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06863584 | SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial | recruiting | Phase 2 | 41 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT05248633 | Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma | recruiting | Phase 2 | 220 | Peking Union Medical College HospitalOTHER | 1 | Jun 5, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Aug 27, 2026source: clinicaltrials